These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11735607)

  • 1. Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making.
    Gobburu JV; Marroum PJ
    Clin Pharmacokinet; 2001; 40(12):883-92. PubMed ID: 11735607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.
    Zhang X; Yang Y; Grimstein M; Fan J; Grillo JA; Huang SM; Zhu H; Wang Y
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S160-S178. PubMed ID: 33205429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The US Food and drug administration: drug information resource for formulary recommendations.
    Marchand HC; Ros BJ; Fine AM; Kremzner ME
    J Manag Care Pharm; 2012; 18(9):713-8. PubMed ID: 23206214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The product label: how pharmacokinetics and pharmacodynamics reach the prescriber.
    Marroum PJ; Gobburu J
    Clin Pharmacokinet; 2002; 41(3):161-9. PubMed ID: 11929317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of population pharmacokinetics in drug development in light of the Food and Drug Administration's 'Guidance for Industry: population pharmacokinetics'.
    Williams PJ; Ette EI
    Clin Pharmacokinet; 2000 Dec; 39(6):385-95. PubMed ID: 11192472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leveraging prior quantitative knowledge to guide drug development decisions and regulatory science recommendations: impact of FDA pharmacometrics during 2004-2006.
    Wang Y; Bhattaram AV; Jadhav PR; Lesko LJ; Madabushi R; Powell JR; Qiu W; Sun H; Yim DS; Zheng JJ; Gobburu JV
    J Clin Pharmacol; 2008 Feb; 48(2):146-56. PubMed ID: 18199891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology.
    Grimstein M; Yang Y; Zhang X; Grillo J; Huang SM; Zineh I; Wang Y
    J Pharm Sci; 2019 Jan; 108(1):21-25. PubMed ID: 30385284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.
    Bhattaram VA; Bonapace C; Chilukuri DM; Duan JZ; Garnett C; Gobburu JV; Jang SH; Kenna L; Lesko LJ; Madabushi R; Men Y; Powell JR; Qiu W; Ramchandani RP; Tornoe CW; Wang Y; Zheng JJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):213-21. PubMed ID: 17259946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications.
    Bhattaram VA; Booth BP; Ramchandani RP; Beasley BN; Wang Y; Tandon V; Duan JZ; Baweja RK; Marroum PJ; Uppoor RS; Rahman NA; Sahajwalla CG; Powell JR; Mehta MU; Gobburu JV
    AAPS J; 2005 Oct; 7(3):E503-12. PubMed ID: 16353928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacometrics at FDA: evolution and impact on decisions.
    Powell JR; Gobburu JV
    Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of statistical and pharmacokinetic-pharmacodynamic modeling and simulation to improve decision-making: A section summary report of the trends and innovations in clinical trial statistics conference.
    Kimko H; Berry S; O'Kelly M; Mehrotra N; Hutmacher M; Sethuraman V
    J Biopharm Stat; 2017; 27(3):554-567. PubMed ID: 28304215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Food and Drug Administration advisory committees and panels: how they are applied to the drug regulatory process.
    Ciociola AA; Karlstadt RG; Pambianco DJ; Woods KL; Ehrenpreis ED;
    Am J Gastroenterol; 2014 Oct; 109(10):1508-12. PubMed ID: 25001252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A drug's life: the pathway to drug approval.
    Keng MK; Wenzell CM; Sekeres MA
    Clin Adv Hematol Oncol; 2013 Oct; 11(10):646-55. PubMed ID: 24518374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The regulation of pharmacogenomics-based drugs and policy making.
    Issa AM
    Curr Top Med Chem; 2004; 4(13):1455-60. PubMed ID: 15379657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics. A regulatory perspective.
    Sun H; Fadiran EO; Jones CD; Lesko L; Huang SM; Higgins K; Hu C; Machado S; Maldonado S; Williams R; Hossain M; Ette EI
    Clin Pharmacokinet; 1999 Jul; 37(1):41-58. PubMed ID: 10451782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of modeling and simulation in drug development and regulatory review.
    Huang SM; Abernethy DR; Wang Y; Zhao P; Zineh I
    J Pharm Sci; 2013 Sep; 102(9):2912-23. PubMed ID: 23712632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions.
    Zhao P; Rowland M; Huang SM
    Clin Pharmacol Ther; 2012 Jul; 92(1):17-20. PubMed ID: 22713733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.
    Paglialunga S; Offman E; Ichhpurani N; Marbury TC; Morimoto BH
    Expert Rev Clin Pharmacol; 2017 Mar; 10(3):273-283. PubMed ID: 27998190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.